Last reviewed · How we verify
hMSC
At a glance
| Generic name | hMSC |
|---|---|
| Also known as | allogeneic mesenchymal bone marrow cells |
| Sponsor | Bernard (Barry) Baumel |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI) (PHASE2)
- AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) (PHASE1)
- Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (PHASE1, PHASE2)
- Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. (PHASE2)
- Alzheimer's Disease Stem Cells Multiple Infusions (PHASE1)
- Expanded Access Using Allogeneic Bone-marrow Derived Human Mesenchymal Stem Cells (Allo-hMSC) for a Individual Parkinson's Disease Subject
- Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hMSC CI brief — competitive landscape report
- hMSC updates RSS · CI watch RSS
- Bernard (Barry) Baumel portfolio CI